License, Collaborative and Employment Agreements and Commitments (Details Textual) (USD $)	12 Months Ended				12 Months Ended					1 Months Ended			12 Months Ended				12 Months Ended						12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2009	Dec. 31, 2013 Mark Pimentel [Member]	Dec. 31, 2013 Option Agreement [Member]	Dec. 31, 2013 Non Refundable Option [Member]	Dec. 31, 2013 Non Refundable Extension [Member]	Dec. 31, 2013 Licensing Agreements [Member]	Dec. 31, 2013 Patents [Member]	Feb. 29, 2012 Jeffrey Riley [Member]	Feb. 29, 2012 C. Evan Ballantyne [Member]	Sep. 30, 2005 Research and Development Arrangement [Member]	Dec. 31, 2012 Intrexon [Member]	Dec. 31, 2011 Intrexon [Member]	Dec. 31, 2013 Intrexon [Member]	Dec. 31, 2013 Intrexon [Member] Research and Development Arrangement [Member]	Dec. 31, 2012 Prev Abr Llc [Member]	Dec. 31, 2013 Cedars-Sinai Medical Center [Member]	Dec. 31, 2012 Office Space In Ann Arbor [Member]	Dec. 31, 2012 Office Space In Rockville [Member]	Dec. 31, 2012 December 31, 2014 [Member]	Dec. 31, 2012 December 31, 2015 [Member]	Dec. 31, 2012 Phase I Clinical Trials [Member]	Dec. 31, 2012 Phase Iii Clinical Trials [Member]	Dec. 31, 2012 Nda Submission In Us [Member]	Dec. 31, 2012 European Medicines Agency Approval [Member]	Dec. 31, 2012 Regulatory Approval In Asian Country [Member]	Dec. 31, 2012 IND Milestone Event [Member]	Dec. 31, 2012 Approval Milestone Event [Member]	Dec. 31, 2012 Field Expansion Fee [Member]	Dec. 31, 2013 First Year [Member]	Dec. 31, 2013 Second Year [Member]	Dec. 31, 2013 Third Year [Member]
License, Collaborative and Employment Agreements and Commitments [Line Items]
Line of Credit Facility, Periodic Payment			$ 197,000
Line of Credit Facility, Periodic Payment, Interest			5,000
Research and Development Expense	6,507,000	12,287,000										460,000	7,800,000
Operating Leases, Rent Expense	68,000	123,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value										1,700,000	1,000,000
Officers Compensation										348,000	298,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	222,500									750,000	425,000
Operating Leases, Future Minimum Payments, Due in Two Years																			33,000
Operating Lease Leasing Term																			extend the term of the lease to December 31, 2014	one year operating lease that may be renewed for two additional terms of one year
Partial Consideration for Execution														Intrexon a number of shares of our common stock equal to 9.995% of the number of shares of the Companys common stock issued
Registration Payment Arrangement, Settlement Alternatives																												The Company also agreed upon the filing of an IND application with the FDA for a Synthetic Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable, the IND Milestone Event), to pay Intrexon either (i) $2.0 million in cash, or (ii) that number of shares of Common Stock (the IND Milestone Shares) having a fair market value equaling $2.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the IND Milestone Event	Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of the regulatory approval of that Synthetic Product (both as applicable, the Approval Milestone Event), the Company agreed to pay to Intrexon either (i) $3.0 million in cash, or (ii) that number of shares of Common Stock (the Approval Milestone Shares) having a fair market value equaling $3.0 million where such fair market value is determined using published market data of the share price for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment of the Approval Milestone Event	The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) $2.0 million in cash for each target in excess of three total that the Company elects, or (ii) that number of shares of Common Stock (the Field Expansion Fee Shares) having a fair market value equaling $2.0 million for each such target that the Company elects in excess of three where such fair market value is determined using published market data establishing the volume-weighted average price for a share of Common Stock over the 30 day period immediately preceding the date of the Field Expansion Fee Closing.
Registration Payment Arrangement, Term		In connection with the transactions contemplated by the Stock Purchase Agreement, and pursuant to the Registration Rights Agreement executed and delivered by the Company to Intrexon, the Company agreed to file a resale registration statement registering the resale of the First Tranche Shares within 120 days of the closing date of such issuance.
Operating Leases, Future Minimum Payments Due, Next Twelve Months																				42,000	50,000	25,000
Research Agreement Fixed Fee																															303,287	316,438	328,758
Milestone Payment																							50,000	100,000	250,000	100,000	100,000
Cash Payment for License Agreement																	100,000
Additional Cash Payment for License Agreement																	135,000
Unregistered Shares Issued to License Agreement																	625,000
Additional Consideration Payable																	50% in cash and 50% in our stock
Stock Issued During Period, Shares, Acquisitions													3,552,210
Development Stage Entities, Equity Issuance, Per Share Amount													$ 0.001	$ 0.001
Prepaid Expense and Other Assets, Current	1,591,000	2,509,000													2,500,000	1,400,000
Payments for Fees						50,000	25,000	150,000	220,000									50,000
Stock Issued During Period, Shares, New Issues					43,342			291,569
Payments to Acquire in Process Research and Development	1,000,000	87,000
Common Stock, Market Value					110.00%													110.00%
Common stock Outstanding Percentage				8.50%														11.50%
Exchange percentage of unregistered common stock	50.00%
Proceeds from (Repurchase of) Equity, Total	$ 3,000,000